Unicycive Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Update
Unicycive Therapeutics Q3 EPS $(0.25) Beats $(0.31) Estimate
Unicycive Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference
Unicycive Therapeutics: 95% Upside Priced Against A Wall Of Dilution And Regulatory Risk
Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate NDA Resubmission, PDUFA Date of March 25, 2027
Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate New Drug Application Resubmission and PDUFA Date of March 25, 2027
Unicycive Therapeutics Receives FDA Acceptance Of Its NDA Resubmission For Oxylanthanum Carbonate For Treatment Of Hyperphosphatemia In Patients With Chronic Kidney Disease On Dialysis
Unicycive Therapeutics (UNCY) Loses 21.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Unicycive Therapeutics Appoints Meredith Manning to Board of Directors
HC Wainwright & Co. Maintains Buy on Unicycive Therapeutics, Lowers Price Target to $13
Unicycive Therapeutics Announces Resubmission of New Drug Application for Oxylanthanum Carbonate
Unicycive Therapeutics Resubmits Its FDA New Drug Application For Oxylanthanum Carbonate For The Treatment Of Hyperphosphatemia In Patients With Chronic Kidney Disease On Dialysis; Expects PDUFA Date Six Months From Resubmission Date
Unicycive Says Suit Alleges Securities Law Violations Over Statements On Oxylanthanum Carbonate FDA Application
Unicycive Therapeutics Discloses Securities Class Action Filed September 3 Against Company And Certain Officers
Unicycive Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Benchmark Maintains Speculative Buy on Unicycive Therapeutics, Raises Price Target to $15
Guggenheim Maintains Buy on Unicycive Therapeutics, Lowers Price Target to $25
B. Riley Securities Reiterates Buy on Unicycive Therapeutics, Lowers Price Target to $20
Unicycive Therapeutics shares rise after second-quarter loss beats forecasts
Unicycive Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.